Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00975182 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
A Phase 1 study of Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 4
- Study locations
NCT00975182 is a Phase 1 study of Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers that has completed, run by Genentech. The registered enrollment target is 58 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT00975182, a Phase 1 study of Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid tumors and patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen.
Conditions Studied
Interventions
- DRUG GDC-0941
- DRUG erlotinib HCl
Study Locations (4)
Other
- - Amsterdam
- - Utrecht
Colorado
- - Aurora
New Jersey
- - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00975182
The ClinicalTrials.gov registry entry for NCT00975182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers appearing as the primary indexed condition, and to 2 interventions - of which GDC-0941 is the first listed.
NCT00975182 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Colorado, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00975182 about?
NCT00975182 is a clinical study titled "A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors". This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid tumors and patients with locally advanced or metastatic non-small cell ...
What is the current status of trial NCT00975182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2009-09. Estimated completion is 2014-09.
What conditions does trial NCT00975182 study?
This clinical trial studies the following conditions: Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers.
What interventions are being tested in trial NCT00975182?
The interventions under investigation include: GDC-0941 (DRUG), erlotinib HCl (DRUG).
Who is sponsoring clinical trial NCT00975182?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00975182 being conducted?
This trial has 4 study locations across Colorado, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.